Awiqli Insulin Launch: Weekly Dosing vs Daily Therapy

The Indian diabetes care landscape has shifted with the introduction of Awiqli, a once-weekly basal insulin injection from the Danish pharmaceutical firm Novo Nordisk. This development aims to simplify treatment regimens for people with type 2 diabetes by reducing the burden of daily injections from 365 to 52 per year. Experts suggest that this change addresses significant barriers to treatment, such as injection fatigue and missed doses, potentially improving long-term health outcomes for patients. 0

The adoption of Awiqli follows the global ONWARDS clinical programme, which included over 4,000 participants in Phase 3a trials. Data indicates that insulin icodec provides glycemic control comparable to, and in some cases better than, traditional once-daily basal insulins, all while maintaining a similar safety profile. However, medical professionals emphasize that once-weekly therapy is not a universal solution; patients requiring the granular flexibility of daily dose adjustments due to fluctuating meal patterns, exercise, or illness may still find conventional daily injections more appropriate for their specific needs. 0

Choosing between weekly and daily insulin requires a personalized approach based on a patient’s unique blood sugar patterns and lifestyle requirements. While convenience is a major advantage for those struggling with consistency, clinicians stress that insulin therapy remains only one component of a holistic diabetes management plan. Healthy habits including balanced nutrition, regular physical activity, and consistent glucose monitoring are essential to achieving optimal health. Patients are encouraged to consult their healthcare providers to determine if switching to a once-weekly regimen is suitable based on factors like kidney function and hypoglycemia risk.